"The addition of Jnana's drug discovery technology and small molecule pipeline in PKU and autoimmune diseases will strengthen our R&D in the Boston area of the US, one of the most important ...

Jnana said in a statement that the funding will allow it to take JNT-517 through proof-of-concept testing in PKU, a genetic disorder caused by an inability to break down the amino acid ...